Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex

含 Ada2a 的组蛋白乙酰转移酶复合物对 TAZ-CAMTA1 转录程序的表观遗传调节

基本信息

  • 批准号:
    10304900
  • 负责人:
  • 金额:
    $ 34.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-12-15 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract TAZ/YAP are transcriptional effectors and proto-oncoproteins of the Hippo pathway, a signal transduction pathway regulating tumor growth and metastasis in multiple cancers including sarcomas. While much has been uncovered with regards to the upstream regulation of TAZ and YAP, little is known about epigenetic regulation of their transcriptional programs, representing a significant gap in knowledge. To address this gap, we utilized the TAZ-CAMTA1 (TC) and YAP-TFE3 (YT) fusion proteins. TC and YT are driving oncoproteins in epithelioid hemangioendothelioma (EHE), a sarcoma arising in adolescents (responsive to PA-16-251, Gene Fusions in Pediatric Sarcomas). TC and YT, hyperactivated forms of TAZ and YAP, are relevant because gene fusions are the most common type of genetic alterations of TAZ/YAP in cancer. Our objective in this proposal is to determine if TC and YT further stimulate TAZ/YAP transcription by altering the epigenome. Our central hypothesis is that TC and YT recruit YEATS2 and ZZZ3, part of the Ada2a-containing (ATAC) histone acetyltransferase complex, which potentiate the TAZ/YAP oncogenic transcriptional programs. This hypothesis is supported by two serial unbiased approaches: BioID mass spectrometry followed by an shRNA screen that identified YEATS2 and ZZZ3 as the proteins most critical for TC driven anchorage independent growth. We plan to test our central hypothesis with the following specific aims utilizing TC, the predominant fusion protein in EHE (85% of EHE): Aim 1) Determine how YEATS2 and ZZZ3 alter the TAZ-CAMTA1 transcriptional program. We will perform ChIP-seq and determine if TC co-localizes with YEATS2 and ZZZ3 on the genome. RNA-seq will be performed in TC expressing cell lines with and without expression of YEATS2 or ZZZ3 to identify their effects on the TC transcriptome. Aim 2) Identify domains of TAZ-CAMTA1, YEATS2, and ZZZ3 required for cellular transformation. The interaction of YEATS2 and ZZZ3 with TC will be dissected by co-immunoprecipitation utilizing deletion mutants. The mutants will be further studied in anchorage independent growth assays we have developed. Aim 3) Determine the contributions of the YEATS2 and ZZZ3 interactions with TAZ-CAMTA1 in vivo. We will use both genetic and pharmacological approaches to inhibit YEATS2/ZZZ3/ATAC function in novel TC transgenic and xenograft sarcoma mouse models and evaluate their effect on tumorigenesis and metastasis. The proposal is innovative because it utilizes TC and YT as well as two serial unbiased approaches to identify YEATS2/ZZZ3/ATAC as novel epigenetic regulators of the TAZ/YAP transcriptome, expanding the focus of the field and addressing a significant gap in knowledge. The project is significant because it identifies YEATS2 and ZZZ3 as novel oncoproteins and drivers in sarcoma and provides a rationale for inhibiting histone modifying complexes as a novel way of targeting the Hippo pathway, which currently lacks a therapeutic target.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Munir Tanas其他文献

Munir Tanas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Munir Tanas', 18)}}的其他基金

Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex
含 Ada2a 的组蛋白乙酰转移酶复合物对 TAZ-CAMTA1 转录程序的表观遗传调节
  • 批准号:
    10524175
  • 财政年份:
    2019
  • 资助金额:
    $ 34.82万
  • 项目类别:
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex
含 Ada2a 的组蛋白乙酰转移酶复合物对 TAZ-CAMTA1 转录程序的表观遗传调节
  • 批准号:
    9884904
  • 财政年份:
    2019
  • 资助金额:
    $ 34.82万
  • 项目类别:
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex
含 Ada2a 的组蛋白乙酰转移酶复合物对 TAZ-CAMTA1 转录程序的表观遗传调节
  • 批准号:
    10527325
  • 财政年份:
    2019
  • 资助金额:
    $ 34.82万
  • 项目类别:
Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex
含 Ada2a 的组蛋白乙酰转移酶复合物对 TAZ-CAMTA1 转录程序的表观遗传调节
  • 批准号:
    10064613
  • 财政年份:
    2019
  • 资助金额:
    $ 34.82万
  • 项目类别:
Upstream regulation of TAZ and YAP in sarcomas: Towards combinatorial therapytargeting the Hippo pathway
肉瘤中 TAZ 和 YAP 的上游调控:针对 Hippo 通路的组合治疗
  • 批准号:
    10661054
  • 财政年份:
    2016
  • 资助金额:
    $ 34.82万
  • 项目类别:
Upstream regulation of TAZ and YAP in sarcomas: Towards combinatorial therapytargeting the Hippo pathway
肉瘤中 TAZ 和 YAP 的上游调控:针对 Hippo 通路的组合治疗
  • 批准号:
    10481426
  • 财政年份:
    2016
  • 资助金额:
    $ 34.82万
  • 项目类别:
Upstream regulation of TAZ and YAP in sarcomas: towards combinatorial therapy targeting the Hippo Pathway
肉瘤中 TAZ 和 YAP 的上游调控:针对 Hippo 通路的组合治疗
  • 批准号:
    9235613
  • 财政年份:
    2016
  • 资助金额:
    $ 34.82万
  • 项目类别:

相似海外基金

Dissecting out differential molecular phenotypes across Lysine(K) AcetylTransferase mutations in mouse development
剖析小鼠发育过程中赖氨酸(K)乙酰转移酶突变的差异分子表型
  • 批准号:
    10727966
  • 财政年份:
    2023
  • 资助金额:
    $ 34.82万
  • 项目类别:
Targeting lysine acetyltransferase MOF/KAT8 in lung cancer
靶向赖氨酸乙酰转移酶 MOF/KAT8 在肺癌中的作用
  • 批准号:
    10601761
  • 财政年份:
    2023
  • 资助金额:
    $ 34.82万
  • 项目类别:
Defining the cell-type specific role of histone acetyltransferase KAT2a in nucleus accumbens D1 medium spiny neurons as a driver of cocaine use disorder
定义组蛋白乙酰转移酶 KAT2a 在伏隔核 D1 中型多棘神经元中作为可卡因使用障碍驱动因素的细胞类型特异性作用
  • 批准号:
    10679238
  • 财政年份:
    2023
  • 资助金额:
    $ 34.82万
  • 项目类别:
Roles of lysine acetyltransferase 6 complexes in cerebral development and neurodevelopmental disorders
赖氨酸乙酰转移酶 6 复合物在大脑发育和神经发育障碍中的作用
  • 批准号:
    479754
  • 财政年份:
    2023
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Operating Grants
Examination of the Histone Acetyltransferase CBP in the Remodelling of Thermogenic Adipose Tissues
组蛋白乙酰转移酶 CBP 在生热脂肪组织重塑中的检测
  • 批准号:
    486467
  • 财政年份:
    2022
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Studentship Programs
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
开发用于癌基因驱动癌症的 p300/CBP 组蛋白乙酰转移酶抑制剂
  • 批准号:
    10344246
  • 财政年份:
    2022
  • 资助金额:
    $ 34.82万
  • 项目类别:
Nuclear activity of carnitine acetyltransferase
肉毒碱乙酰转移酶的核活性
  • 批准号:
    RGPIN-2018-06089
  • 财政年份:
    2022
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Discovery Grants Program - Individual
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
开发用于癌基因驱动癌症的 p300/CBP 组蛋白乙酰转移酶抑制剂
  • 批准号:
    10627744
  • 财政年份:
    2022
  • 资助金额:
    $ 34.82万
  • 项目类别:
Structural and functional studies of histone acetyltransferase complexes
组蛋白乙酰转移酶复合物的结构和功能研究
  • 批准号:
    RGPIN-2018-03951
  • 财政年份:
    2022
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Discovery Grants Program - Individual
Characterizing the role of the NuA3 histone acetyltransferase complex during transcription
表征 NuA3 组蛋白乙酰转移酶复合物在转录过程中的作用
  • 批准号:
    557615-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Postdoctoral Fellowships
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了